Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • J&J axes eye disease gene therapy after key phase 2b readout

J&J axes eye disease gene therapy after key phase 2b readout

July 15, 2026Posted inBiotechnology

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.

Post navigation

Previous Post
optical-singularity-protractor-enables-rotating-metrology-with-neuromorphic-sensors Optical Singularity Protractor Enables Rotating Metrology with Neuromorphic Sensors
Next Post
Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Recent Posts

  • Quantum materials breakthrough may enable electronics in extreme environments
  • Association for Molecular Pathology Names 2026 Award Winners
  • Smart Ring Discretion Challenged by New Findings
  • Compact genetic switch offers new potential therapies for drug-resistant epilepsy
  • Federal Ginseng Rules Struggle to Accurately Predict Plant Health

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top